Editor’s note: Seeking Alpha is proud to join SA’s Undercovered Dozen series as our newest contributing analyst. You can be one of them! Submit your article for review by our editors and share your best investment ideas. Earn money by submitting articles and earn SA Premium perks. access. Click here for more information »
cassp/E+ via Getty Images
introduction
There’s a lot to like about our first weekly edition of the “Undercovered” Dozen. Here are the ideas published June 1-6.
So far, we have published the following articles each month:
Going forward, we aim to publish these “unreleased” features on a weekly basis to provide you with more timely information and a regular source of potential new ideas to sift through for us. Community. Keep an eye out and follow these on Fridays SA’s Undercovered Dozen series To ensure you don’t miss anything.
Today we bring you “Strong Sell” articles on stocks being featured for the first time. There are a number of biotech ideas highlighted, three “Strong Buys” and a microcap tech and uranium company featured. Also, there are a number of stocks featured today that haven’t been featured on this site for several months.
Let’s take a look at what these private equity and ideas mean to you, and let us know your thoughts below: Did any of these stand out?
“of stocks Logistics characteristics of the Americas (LPAAs) experienced extreme volatility following reports that it was being added to the Russell Microcap Index. The company manages 7.3 million square feet of Class A logistics real estate and is primarily focused on the e-commerce market. Despite its growth potential, the company’s stock is currently overvalued, and the company is highly leveraged and has potential issues with its Colombian assets.
“There is a lot of confusion surrounding Logistic Properties of the Americas right now, and that is because it is a new entrant in the public markets. Prior to March 27th of this year, the businesses managed by Logistic Properties of the Americas were managed by a private company called Latam Logistic Properties SA. However, that company and the Cayman Islands SPAC have both been publicly traded. Merged With a newly formed subsidiary under a new corporation known as Logistic Properties of the Americas.”
“General American Investors, Inc. (Gum) is a closed-end fund that invests in a diversified pool of shares primarily from large US publicly traded stocks. The GAM CEF uses approximately 12% leverage in the form of preferred stocks and pays 5.95% quarterly distributions. GAM’s past performance has been strong, especially over the long term. In some ways, the fund is a proxy for the S&P 500 Index in terms of capital appreciation while benefiting from substantial returns, albeit with fluctuations from year to year.
“If history is any guide, this fund’s distributions have averaged over 6%, and anything above 6% should be treated as a bonus. Overall, General American Investors is a great fund for buy-and-hold income investors who don’t need a very high income and want to invest for long-term capital appreciation.”
“The last time I visited CRISPR Therapeutics (CRSP) in January. CRISPR’s Casgevy is a gene therapy product targeting transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD). Casgevy was approved in the United States in December 2023. “Overall, I am upgrading my recommendation from ‘sell’ to ‘hold’ based on the recent valuation adjustment and the company’s prudent management of operating expenses, which has extended its cash runway until the market outlook becomes more certain. However, prospective and current investors should be aware of the speculative nature of investments like CRISPR. This may be a good choice for a barbell portfolio.”
“In the midst of feeling depressed, Enovix (Envex) began full operations in Q1 2024. Key manufacturing milestones have been achieved, with Enovix expecting to manufacture and deliver the first samples using EX-1M technology in Q2 2024, and Fab2 to be production ready in the second half of 2024.
“While there is some good news to celebrate after this earnings report, Enovix still has a lot of work to do before it can become a top-tier battery company. For now, the company has succeeded in developing a product that is better than others available on the market, first producing samples and then building a factory that can produce at scale, and garnering interest from major smartphone manufacturers to sample these batteries.”
“Voyager Therapeutics, Inc. (Vigle) is a clinical-stage biotechnology company focused on developing novel therapeutics, primarily gene-based, for the treatment of diseases affecting the nervous system, including Alzheimer’s disease (“AD”), amyotrophic lateral sclerosis (“ALS”), Friedreich’s ataxia, Huntington’s disease (“HD”) and Parkinson’s disease (“PD”).
“We believe Voyager Therapeutics has demonstrated sufficient pipeline progress to justify an upgrade to its ratings. Not only did the company submit its IND for VY-TAU01 ahead of schedule, but the FDA approval was also granted quickly, which we think is a great sign. The start of clinical trials is the step that investors, including myself, have been waiting for, so we are very pleased that it took less than a month from FDA approval to start trials.”
“Adams Natural Resources Fund (Human Resources Professional) is a closed-end fund that invests primarily in energy and natural resource stocks. The fund is currently trading at a 14% discount to its net asset value. The fund has demonstrated solid performance with gains of just over 13% over the past year. We believe this fund is an ideal way to invest in the largest and most popular energy stocks. Additionally, you get all the benefits and risk mitigation that come with the diversification that this fund offers while only owning one fund.
“I believe PEOs are an ideal way to invest in the energy sector and gain diversification and above-average dividend yields. Long-term energy demand is likely to remain strong due to population growth, a growing middle class in many emerging market economies, and large power demand from AI and other new industries, so I view PEOs as a strong buy, especially on dips.”
“I first analyzed POET Technologies. (poets), I initiated a Buy rating on the stock, but the company is experiencing a favorable change in perception due to a YouTube video by “ticker symbol: YOU.” The video has already been viewed almost 150,000 times, and interest and trading volume in the stock has exploded as POET was deemed a possible big winner in the booming AI device market.
“Meanwhile, POET has raised significant capital at these elevated levels of C$3.07 and C$2.90, which is 122% and 110% above the stock price before the video release and about three times the price of its previous share issue earlier this year. This capital increase, in my eyes, mitigates the most significant risk for the company. In addition, POET recently won an important design order from Foxconn Interconnect Technology in the AI market, which further validates the company’s technology and gives the company a strong partner for commercialization. Therefore, with the mitigated financing risk and improved commercial outlook, I have upgraded my rating on POET to Strong Buy. Despite the elevated price levels, I believe the company still has great potential.”
Five others worth mentioning
Uranium royalties: the cheapest system in history
“We evaluate Uranium Royalties “Valuations have improved and investors could benefit if uranium prices rise again, but we are continuing to hold.”
Halliburton: Downside risks emerge
“Halliburton’s While the stock may look relatively cheap, profit margins are unlikely to be sustained at current levels.”
Clover Health: New business model a game changer
“I am evaluating Clover Health With a target price of $2.45, it suggests a 120% upside from current levels, leading to a buy recommendation.”
Upcoming Pivotal HELIOS-B Data Will Have a Significant Impact on Alnylam’s Valuation
“Alnylam PharmaceuticalsThe company is expected to release clinical data from its HELIOS-B study in late June or early July, which will have a significant impact on the company’s stock price.”
Roivant Sciences: Significant share repurchase program undertaken and plans to continue
“Roivant Sciences The company is undervalued with a market cap of $8.37 billion and $6 billion in cash.”
Editor’s Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.
